Compounds > metformin

metformin and lenvatinib

metformin has been researched along with lenvatinib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, J; Dai, L; Liu, L; Liu, Q; Roessler, S; Shi, L; Wei, T; Xiong, L; Yan, L; Yang, J; Zhang, Q; Zhang, W1
Cen, X; Cheng, Y; Lu, J; Lu, Y; Luo, C; Wang, F; Xie, C; Yin, Z; Zhan, P1

Other Studies

3 other study(ies) available for metformin and lenvatinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma.
    Oncogene, 2023, Volume: 42, Issue:19

    Topics: Animals; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; PPAR gamma

2023
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway.
    Liver international : official journal of the International Association for the Study of the Liver, 2023, Volume: 43, Issue:7

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Metformin; Phenylurea Compounds; Proto-Oncogene Proteins c-akt

2023